<DOC>
	<DOCNO>NCT00749424</DOCNO>
	<brief_summary>The objective study compare safety effectiveness two different approach treat bifurcational lesion CYPHER SELECTâ„¢ Sirolimus-eluting Balloon-expandable Coronary Stent , Cordis Corp ) : ) `` crush '' technique stent branch vs. b ) provisional T stenting technique side branch .</brief_summary>
	<brief_title>The Study Crushing Technique Application Using SES Coronary Bifurcations .</brief_title>
	<detailed_description>This prospective , randomize study conduct 5 center Italy . All patient meet eligibility criterion treat Cypher SelectTM Stent Stent Delivery System ( SDS ) . Patients repeat angiography six month , clinical follow-up 2 year .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Is male nonpregnant female patient &gt; = 18 year age [ NOTE : Females childbearing potential must negative pregnancy test ] ; 2 . Has diagnosis angina pectoris defined Canadian Cardiovascular Society Classification ( CCS I , II , III , IV ) OR unstable angina pectoris ( Braunwald Classification B &amp; C , III ) OR document silent ischemia ; 3 . Has least TIMI I coronary flow main side branch ; 4 . Involves single treatment de novo bifurcation lesion native coronary artery patient single multivessel disease ; patient multiple lesion include lesion treat index procedure successfully treat prior treatment bifurcation lesion ; 5 . Has true bifurcation lesion define stenosis &gt; 50 % main branch ostium side branch ; 6 . Has maximum treatable main side branch lesion length &lt; =28 mm ; 7 . Has main branch vessel &gt; = 2.5 mm &lt; = 3.5 mm diameter online QCA proximal bifurcation ; 8 . Has side branch vessel &gt; = 2.25 mm &lt; = 3.5 mm diameter online QCA ; 9 . Is acceptable candidate coronary artery bypass surgery ( CABG ) ; 10 . Is willing comply specify followup evaluation ; 11 . The patient legally authorize representative must provide write informed consent prior procedure . 1 . Patient experience Qwave nonQwave myocardial infarction document elevation CK level &gt; 2 time normal CKMB level &gt; 3 time normal within precede 24 hour and/or CK CKMB enzymes remain normal time treatment ; 2 . Has unstable angina classify Braunwald A IIII , B &amp; C III ; 3 . Has bifurcation lesion non protect left main ; 4 . Has ejection fraction &lt; = 35 % ; 5 . Has know allergy follow : aspirin , clopidogrel bisulfate ( Plavix ) ticlopidine ( Ticlid ) , heparin , sirolimus ; 6 . Has know serious allergy contrast medium stainless steel manage medically ; 7 . Has impair renal function ( creatinine &gt; 3.0 mg/dl ) ; 8 . There presence thrombus bifurcation lesion ; 9 . Has target lesion excessive tortuousity unsuitable stent delivery deployment ; 10 . Has totally occlude vessel ; 11 . Is recipient heart transplant ; 12 . Has significant medical condition investigator 's opinion may interfere patient 's optimal participation study ; 13 . Is currently participate investigational drug another device study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>